We report the case of a woman treated for an ovarian cancer who ultimately developed terminal renal failure in the frame of a haemolytic uraemic syndrome induced by prolonged gemcitabine therapy. This case illustrates the need of a systematic screening for haemolytic uraemic syndrome in patients receiving protracted gemcitabine for over three months.

(BELD J ONCOL MED 2013;7(2):50–52)